MedTrace Logo

Inflammation REduction to Prevent cArdiovascular Injury in Renal Disease (REPAIR)

NCT06203977 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-03-12

No results posted yet for this study

Summary

Phase 1 basket trial including 2 open-label single-arm cohorts: REPAIR CKD cohort and REPAIR Dialysis cohort. Open label colchicine 0.3 mg daily for 8 weeks followed, in patients who tolerated the 0.3 mg dose, by forced titration to 0.6 mg daily for 8 weeks.

Conditions

  • Chronic Kidney Diseases
  • Renal Failure

Interventions

DRUG

Colchicine

0.3mg and 0.6mg tablets

Sponsors & Collaborators

  • Hamilton Academic Health Sciences Organization

    collaborator OTHER

  • St. Joseph's Health Care London

    collaborator OTHER

  • Hamilton Health Sciences Corporation

    lead OTHER

Principal Investigators

  • Michael Walsh, MD, PhD · McMaster University

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-15
Primary Completion
2026-05-31
Completion
2026-05-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06203977 on ClinicalTrials.gov